FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021251179> ?p ?o ?g. }

• W2021251179 endingPage "720" @default.
• W2021251179 startingPage "713" @default.
• W2021251179 abstract "α-Glucosidase (EC 3.2.1.20) enzyme belongs to the glycosidase family enzymes, cleave the glycosidic bond of the oligosaccharides that liberate glucose and its inhibition retards the carbohydrate digestion. In the present review, we have discussed the structural features of different α-glucosidase inhibitors (small molecules) responsible for the inhibitory activities. The reported computational studies including, QSAR, pharmacophore modelling, homology models, docking (with analogs enzymes), etc revealed that the topological, electronic and hydrophobicity properties determine the interactions of those molecules. The aromatic substituents connected with flexible bonds in the molecules have significant effect on the interactions, which may due to the presence of aromatic amino acid residues in the active site. The reported homology modelled and other analogs enzymes (enzymes of other species) also confirmed the existence of aromatic residue (amino acids) especially, histidine, phenylalanine and tyrosine in their active site along with the polar (glutamic and aspartic acids) residues. Multiple sequence alignments of the α-glucosidase enzymes (from different species) described that the abovementioned amino acid residues are present in the active site of all the studied enzymes. Recently, Celgosivir (MIGENIX Inc) is an oral prodrug of the natural product castanospermine used for the treatment of HCV infection by inhibiting α-glucosidase I. BMN-701 is an α-glucosidase inhibitors in the phase I pipeline (BioMarine) for the treatment of Pompe diseases. CKD-711 and CKD-711a are aminooligosaccharide α-glucosidase inhibitors and the in vitro study of CKD-711 showed similar effects to acarbose on porcine intestinal maltase and sucrase (IC50s of 2.5 and 0.5 μg/ml). This review also concluded that many α-glucosidases inhibitors obtained from natural products are used for the treatment of various carbohydrate mediated diseases. The structural analysis of these synthetic and natural derivatives guide for the development of novel semisynthetic/synthetic α-glucosidase inhibitors with free of toxicities. Keywords: α-Glucosidases, HIV, QSAR, hydrophobicity, vdW surface area." @default.
• W2021251179 created "2016-06-24" @default.
• W2021251179 creator A5006973363 @default.
• W2021251179 creator A5048088473 @default.
• W2021251179 creator A5072586254 @default.
• W2021251179 date "2012-05-01" @default.
• W2021251179 modified "2023-09-26" @default.
• W2021251179 title "Studies on α-Glucosidase Inhibitors Development: Magic Molecules for the Treatment of Carbohydrate Mediated Diseases" @default.
• W2021251179 cites W1321684 @default.
• W2021251179 cites W1531607776 @default.
• W2021251179 cites W1964038824 @default.
• W2021251179 cites W1966467057 @default.
• W2021251179 cites W1968296589 @default.
• W2021251179 cites W1968414605 @default.
• W2021251179 cites W1973559771 @default.
• W2021251179 cites W1974385664 @default.
• W2021251179 cites W1974724133 @default.
• W2021251179 cites W1978288432 @default.
• W2021251179 cites W1979635562 @default.
• W2021251179 cites W1984871623 @default.
• W2021251179 cites W1985614577 @default.
• W2021251179 cites W1994901740 @default.
• W2021251179 cites W2001268716 @default.
• W2021251179 cites W2003885425 @default.
• W2021251179 cites W2004018987 @default.
• W2021251179 cites W2025384353 @default.
• W2021251179 cites W2028657736 @default.
• W2021251179 cites W2028834863 @default.
• W2021251179 cites W2028956857 @default.
• W2021251179 cites W2030625213 @default.
• W2021251179 cites W2039476804 @default.
• W2021251179 cites W2040689267 @default.
• W2021251179 cites W2047151337 @default.
• W2021251179 cites W2048682373 @default.
• W2021251179 cites W2058403436 @default.
• W2021251179 cites W2058484488 @default.
• W2021251179 cites W2058583056 @default.
• W2021251179 cites W2059272055 @default.
• W2021251179 cites W2059796456 @default.
• W2021251179 cites W2060952302 @default.
• W2021251179 cites W2064413316 @default.
• W2021251179 cites W2068711176 @default.
• W2021251179 cites W2070516699 @default.
• W2021251179 cites W2070658650 @default.
• W2021251179 cites W2075222406 @default.
• W2021251179 cites W2078569751 @default.
• W2021251179 cites W2079341791 @default.
• W2021251179 cites W2083025941 @default.
• W2021251179 cites W2088423161 @default.
• W2021251179 cites W2090562487 @default.
• W2021251179 cites W2092645001 @default.
• W2021251179 cites W2094012022 @default.
• W2021251179 cites W2116068036 @default.
• W2021251179 cites W2121373279 @default.
• W2021251179 cites W2135975877 @default.
• W2021251179 cites W2149369491 @default.
• W2021251179 cites W2151701444 @default.
• W2021251179 cites W2157033775 @default.
• W2021251179 cites W2159995178 @default.
• W2021251179 cites W2171967505 @default.
• W2021251179 cites W2181724634 @default.
• W2021251179 cites W2186766174 @default.
• W2021251179 cites W2218667365 @default.
• W2021251179 cites W2315098045 @default.
• W2021251179 cites W2321236430 @default.
• W2021251179 cites W2951418708 @default.
• W2021251179 cites W2951827888 @default.
• W2021251179 doi "https://doi.org/10.2174/138955712801264837" @default.
• W2021251179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22512574" @default.
• W2021251179 hasPublicationYear "2012" @default.
• W2021251179 type Work @default.
• W2021251179 sameAs 2021251179 @default.
• W2021251179 citedByCount "55" @default.
• W2021251179 countsByYear W20212511792013 @default.
• W2021251179 countsByYear W20212511792014 @default.
• W2021251179 countsByYear W20212511792015 @default.
• W2021251179 countsByYear W20212511792016 @default.
• W2021251179 countsByYear W20212511792017 @default.
• W2021251179 countsByYear W20212511792018 @default.
• W2021251179 countsByYear W20212511792019 @default.
• W2021251179 countsByYear W20212511792020 @default.
• W2021251179 countsByYear W20212511792021 @default.
• W2021251179 countsByYear W20212511792022 @default.
• W2021251179 countsByYear W20212511792023 @default.
• W2021251179 crossrefType "journal-article" @default.
• W2021251179 hasAuthorship W2021251179A5006973363 @default.
• W2021251179 hasAuthorship W2021251179A5048088473 @default.
• W2021251179 hasAuthorship W2021251179A5072586254 @default.
• W2021251179 hasConcept C159110408 @default.
• W2021251179 hasConcept C181199279 @default.
• W2021251179 hasConcept C185592680 @default.
• W2021251179 hasConcept C196032511 @default.
• W2021251179 hasConcept C2776617576 @default.
• W2021251179 hasConcept C41183919 @default.
• W2021251179 hasConcept C41685203 @default.
• W2021251179 hasConcept C515207424 @default.
• W2021251179 hasConcept C55493867 @default.
• W2021251179 hasConcept C56173144 @default.

• next